We aim to develop innovative, RNA-based therapeutics to address unmet medical needs for patients with genetic disorders.

All neuromuscular disorders

Duchenne Muscular Dystrophy Patient Stories

Read all patient stories


Compound Discovery Pre-clinical Phase I / II Phase III
13% of DMD patients
6% of DMD patients
8% of DMD patients
8% of DMD patients
4% of DMD patients
2% of DMD patients

Discover our Products

Understanding DMD

About Prosensa

Prosensa is a biotechnology company engaged in the discovery, development and commercialization of ribonucleic acid (RNA) modulating therapeutics. The company targets the treatment of genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy and Huntington’s disease. Our clinical portfolio of RNA-based product candidates is focused on the treatment of DMD. Each of our DMD compounds has been granted orphan drug status in the United States and the European Union.

More about Prosensa

RNA Modulation

RNA-modulating therapeutics provide a powerful tool for targeted modulation of gene expression. Our unique proprietary technology platform employs single-stranded RNA-based antisense oligonucleotides (AONs) to correct mutated mRNA causing life threatening disorders.

More about RNA-Modulation

Exon Skipping

Our exon skipping technology is based on interference with exon inclusion signals during the splicing of the pre-mRNA, in order to induce the skipping of the targeted exon from the mature mRNA (messenger RNA) and to restore the level of functional transcripts.

More about Exon Skipping